Switch theme
Sign up to access all valuation multiples
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company’s products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
1984
1.6K+
LTM Revenue $405M
LTM EBITDA $77.3M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Artivion has a last 12-month revenue (LTM) of $405M and a last 12-month EBITDA of $77.3M.
In the most recent fiscal year, Artivion achieved revenue of $389M and an EBITDA of $51.0M.
Artivion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Artivion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $405M | XXX | $389M | XXX | XXX | XXX |
| Gross Profit | $261M | XXX | $249M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $77.3M | XXX | $51.0M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $35.0M | XXX | $38.9M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | -$5.7M | XXX | -$13.4M | XXX | XXX | XXX |
| Net Margin | -1% | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $261M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Artivion's stock price is $30.
Artivion has current market cap of $1.4B, and EV of $1.7B.
See Artivion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.4B | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Artivion has market cap of $1.4B and EV of $1.7B.
Artivion's trades at 4.4x EV/Revenue multiple, and 33.7x EV/EBITDA.
Equity research analysts estimate Artivion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Artivion has a P/E ratio of -245.0x.
See valuation multiples for Artivion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 22.2x | XXX | 33.7x | XXX | XXX | XXX |
| EV/EBIT | 49.0x | XXX | 44.1x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -245.0x | XXX | -104.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 155.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArtivion's last 12 month revenue growth is 10%
Artivion's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Artivion's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Artivion's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Artivion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 79% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Artivion acquired XXX companies to date.
Last acquisition by Artivion was XXXXXXXX, XXXXX XXXXX XXXXXX . Artivion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Artivion founded? | Artivion was founded in 1984. |
| Where is Artivion headquartered? | Artivion is headquartered in United States of America. |
| How many employees does Artivion have? | As of today, Artivion has 1.6K+ employees. |
| Who is the CEO of Artivion? | Artivion's CEO is Mr. James Patrick Mackin. |
| Is Artivion publicy listed? | Yes, Artivion is a public company listed on NYS. |
| What is the stock symbol of Artivion? | Artivion trades under AORT ticker. |
| When did Artivion go public? | Artivion went public in 1993. |
| Who are competitors of Artivion? | Similar companies to Artivion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Artivion? | Artivion's current market cap is $1.4B |
| What is the current revenue of Artivion? | Artivion's last 12 months revenue is $405M. |
| What is the current revenue growth of Artivion? | Artivion revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Artivion? | Current revenue multiple of Artivion is 4.2x. |
| Is Artivion profitable? | Yes, Artivion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Artivion? | Artivion's last 12 months EBITDA is $77.3M. |
| What is Artivion's EBITDA margin? | Artivion's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Artivion? | Current EBITDA multiple of Artivion is 22.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
